GlaxoSmithKline S.A.E Cash Flow Statement

Financials in millions EGP. Fiscal year is January - December.

Millions EGP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	213.23	173.98	60.46	735.38	154.64
Depreciation & Amortization	61.47	52.92	47.79	49.81	57.19
Loss (Gain) From Sale of Assets	-0.48	2.4	-0.17	-5.94	-0.24
Asset Writedown & Restructuring Costs	-	-	137.65	101	-
Loss (Gain) on Equity Investments	-35.3	-1	18.12	-12.15	9.21
Provision & Write-off of Bad Debts	-5.32	64.64	-18.66	11.01	30.79
Other Operating Activities	230.83	386.52	24.11	-530.26	89.78
Change in Accounts Receivable	-142.62	-333.87	-366.5	-231.15	-18.53
Change in Inventory	-649.32	-420.25	-263.59	-47.2	-42.95
Change in Accounts Payable	142.09	64.9	156.24	-322.32	45.45
Change in Other Net Operating Assets	426.25	-394.38	506.84	-82.97	-133.15
Operating Cash Flow	240.83	-404.15	302.27	1,036	192.19
Operating Cash Flow Growth	-	-	-70.82%	439.06%	-
Capital Expenditures	-177.28	-124.34	-77.08	-48.76	-35.76
Sale of Property, Plant & Equipment	0.61	-	5.42	6.99	0.61
Other Investing Activities	292.05	-101.72	157.15	-200	-
Investing Cash Flow	115.39	-226.07	85.5	-241.77	-35.15
Short-Term Debt Repaid	-	-	-	-118.21	-27.52
Long-Term Debt Repaid	-43.06	-43.38	-28.98	-19.21	-24.11
Total Debt Repaid	-43.06	-43.38	-28.98	-137.43	-51.63
Net Debt Issued (Repaid)	-43.06	-43.38	-28.98	-137.43	-51.63
Common Dividends Paid	-14.13	-69.67	-131.59	-111.04	-5.58
Other Financing Activities	105.18	-10.6	16.3	-33.5	-48.42
Financing Cash Flow	48	-123.66	-144.28	-281.97	-105.63
Net Cash Flow	404.22	-753.87	243.49	512.29	51.41
Free Cash Flow	63.55	-528.49	225.2	987.26	156.43
Free Cash Flow Growth	-	-	-77.19%	531.14%	-
Free Cash Flow Margin	1.70%	-17.67%	10.05%	54.15%	8.63%
Free Cash Flow Per Share	0.76	-6.33	2.70	11.82	1.87
Cash Interest Paid	3.35	10.6	37.96	33.5	48.67
Cash Income Tax Paid	108.42	48.27	173.04	10.72	29.97
Levered Free Cash Flow	319.89	-523.15	178.77	108.37	49.65
Unlevered Free Cash Flow	327.15	-516.53	202.5	129.31	80.07
Change in Working Capital	-223.6	-1,084	32.99	-683.64	-149.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.